Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size By Type (Insulin, rHGH), By Application (Oncology, Chronic Diseases), By Region, And Segment Forecasts, 2023 to 2032

The Global Recombinant Non-Glycosylated Proteins Biosimilars Market was valued at USD 3.1 billion in 2023 and is projected to reach USD 7.4 billion by 2031, growing at a CAGR of 11.6% during the forecast period of 2023-2031. The market growth is driven by the rising prevalence of chronic diseases, increasing demand for cost-effective biologics, and expanding biosimilar approvals across key markets. Recombinant non-glycosylated proteins biosimilars, such as insulin, somatropin, and filgrastim, play a crucial role in the treatment of diabetes, cancer, growth hormone deficiencies, and other life-threatening conditions.

Growing acceptance among healthcare providers and patients, favorable regulatory frameworks, and patent expirations of major biologic drugs further accelerate the demand for recombinant non-glycosylated proteins biosimilars globally.

Drivers:

Increasing Prevalence of Chronic Diseases:

The global rise in chronic illnesses, including diabetes, cancer, and autoimmune disorders, fuels the demand for affordable therapeutic options like biosimilars to ensure wider accessibility and cost reduction.

Regulatory Support for Biosimilar Approvals:

Regulatory bodies like the FDA (U.S.) and EMA (Europe) are facilitating faster biosimilar approvals, creating a conducive environment for market growth and encouraging new entrants.

Cost-effectiveness and Market Accessibility:

Biosimilars offer substantial cost savings compared to originator biologics, driving their adoption in healthcare systems, especially in price-sensitive regions.

Restraints:

Manufacturing Complexity:

Recombinant non-glycosylated proteins biosimilars require advanced biotechnological expertise for production, which can pose manufacturing challenges and limit smaller companies' entry.

Market Penetration Challenges:

Despite increasing acceptance, biosimilar penetration faces hurdles due to physician hesitancy, lack of awareness, and brand loyalty towards original biologics in certain regions.

Opportunity:

Expansion in Emerging Markets:

Emerging economies like India, China, and Brazil present lucrative growth opportunities driven by improving healthcare infrastructure and rising healthcare expenditure.

Increasing Collaborations and Partnerships:

Strategic collaborations between biosimilar manufacturers and local pharmaceutical companies can foster faster market penetration and product accessibility.

Market by System Type Insights:

By system type, the Filgrastim Biosimilars segment held the largest market share in 2023 due to its widespread use in oncology for neutropenia treatment. The segment is projected to maintain its dominance, supported by growing cancer incidences globally.

The Insulin Biosimilars segment is expected to witness the fastest growth during the forecast period, driven by the global diabetes epidemic and increasing demand for affordable insulin therapy.

Market by End-use Insights:

Hospitals accounted for the largest end-use segment in 2023, with over 45% market share. The high patient inflow for chronic disease treatment and favorable reimbursement policies fuel the segment's growth.

The Retail Pharmacies segment is anticipated to exhibit notable growth due to increasing over-the-counter availability of biosimilar products and improved patient accessibility.

Market by Regional Insights:

North America dominated the global recombinant non-glycosylated proteins biosimilars market in 2023, attributed to advanced healthcare systems, high biologics expenditure, and robust regulatory approvals.

Asia-Pacific is poised to witness the fastest CAGR during 2023-2031, driven by expanding healthcare coverage, increasing awareness of biosimilars, and growing chronic disease burden in countries like China, India, and Japan.

Competitive Scenario:

Key players operating in the global recombinant non-glycosylated proteins biosimilars market include:

Pfizer Inc.

Novartis AG (Sandoz)

Biocon Limited

Amgen Inc.

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Dr. Reddy’s Laboratories Ltd.

Celltrion Inc.

Samsung Bioepis

Boehringer Ingelheim International GmbH

These companies are focusing on expanding their biosimilar portfolios, engaging in strategic partnerships, and investing in R&D to strengthen their global presence.

Scope of Work – Global Recombinant Non-Glycosylated Proteins Biosimilars Market

Report Metric Details

Market Size (2023) USD 3.1 billion

Projected Market Size (2031) USD 7.4 billion

CAGR (2023-2031) 11.6%

Key Segments by System Type Filgrastim Biosimilars, Insulin Biosimilars, Somatropin Biosimilars

Key Segments by End-use Hospitals, Retail Pharmacies, Specialty Clinics

Leading Region North America

Key Players Pfizer Inc., Novartis AG, Biocon Limited, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd.

Growth Drivers Increasing prevalence of chronic diseases, Regulatory support for biosimilar approvals, Cost-effectiveness

Opportunities Expansion in emerging markets, Increasing collaborations and partnerships

Key Market Developments:

In 2023, Pfizer Inc. launched a new biosimilar filgrastim product in Europe to enhance its oncology portfolio.

In 2024, Biocon Limited expanded its biosimilar insulin production facility in Malaysia to meet the growing global demand.

In 2025, Amgen Inc. received FDA approval for its somatropin biosimilar, strengthening its foothold in the endocrinology segment.

FAQs:

1. What is the current market size of the Global Recombinant Non-Glycosylated Proteins Biosimilars Market?

The market was valued at USD 3.1 billion in 2023.

2. What is the major growth driver of the Global Recombinant Non-Glycosylated Proteins Biosimilars Market?

The increasing prevalence of chronic diseases and growing demand for affordable biologic therapies are the primary growth drivers.

3. Which is the largest region during the forecast period in the Global Recombinant Non-Glycosylated Proteins Biosimilars Market?

North America holds the largest market share due to robust healthcare infrastructure and supportive regulatory environment.

4. Which segment accounted for the largest market share in the Global Recombinant Non-Glycosylated Proteins Biosimilars Market?

The Filgrastim Biosimilars segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Recombinant Non-Glycosylated Proteins Biosimilars Market?

Key players include Pfizer Inc., Novartis AG, Biocon Limited, Amgen Inc., Mylan N.V., and Teva Pharmaceutical Industries Ltd.